$-0.11 EPS Expected for Galectin Therapeutics, Inc. (GALT)

March 1, 2018 - By Adrian Erickson

 $ 0.11 EPS Expected for Galectin Therapeutics, Inc. (GALT)
Investors sentiment decreased to 0.67 in Q3 2017. Its down 1.22, from 1.89 in 2017Q2. It dived, as 7 investors sold Galectin Therapeutics, Inc. shares while 8 reduced holdings. 4 funds opened positions while 6 raised stakes. 3.22 million shares or 4.39% less from 3.37 million shares in 2017Q2 were reported.
Cutter Brokerage holds 54,600 shares or 0.05% of its portfolio. First Republic Inv Management reported 26,000 shares. Goldman Sachs Group Inc Inc holds 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 14,049 shares. Grp Incorporated One Trading Limited Partnership owns 23,052 shares for 0% of their portfolio. Sei invested in 3,800 shares or 0% of the stock. Us Bancshares De accumulated 118,921 shares. Tci Wealth Advisors holds 300 shares or 0% of its portfolio. Geode Capital Limited Company owns 195,411 shares. Benchmark Capital has 0.32% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT). Buckingham Asset Mngmt Lc invested in 50,000 shares. Dynamic Solutions Ltd Llc owns 10,000 shares for 0.01% of their portfolio. Vanguard Grp Inc Inc reported 0% stake. California Employees Retirement reported 23,450 shares or 0% of all its holdings. Deutsche State Bank Ag holds 0% or 2 shares in its portfolio. California-based Cetera Advisor Ltd Liability Corporation has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT).

Since January 25, 2018, it had 2 buys, and 2 selling transactions for $2.64 million activity. 10X Fund – L.P. had sold 244,444 shares worth $1.33 million. $1.33 million worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) was sold by CZIRR JAMES C on Thursday, January 25.

Analysts expect Galectin Therapeutics, Inc. (NASDAQ:GALT) to report $-0.11 EPS on March, 27.They anticipate $0.02 EPS change or 15.38 % from last quarter’s $-0.13 EPS. After having $-0.13 EPS previously, Galectin Therapeutics, Inc.’s analysts see -15.38 % EPS growth. The stock decreased 0.97% or $0.04 during the last trading session, reaching $4.07. About 43,057 shares traded. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 62.09% since March 1, 2017 and is uptrending. It has outperformed by 45.39% the S&P500.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Ratings Coverage

Among 5 analysts covering Galectin Therapeutics (NASDAQ:GALT), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Galectin Therapeutics had 12 analyst reports since September 21, 2015 according to SRatingsIntel. The rating was maintained by Roth Capital with “Buy” on Thursday, December 7. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, June 14 report. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) earned “Buy” rating by H.C. Wainwright on Monday, September 21. As per Thursday, January 4, the company rating was maintained by Roth Capital. The firm earned “Neutral” rating on Thursday, September 29 by H.C. Wainwright. H.C. Wainwright upgraded it to “Buy” rating and $3.50 target in Thursday, March 30 report. TH Capital downgraded the stock to “Sell” rating in Wednesday, September 28 report. The rating was reinitiated by H.C. Wainwright with “Buy” on Monday, March 28. The stock has “Sell” rating by Roth Capital on Wednesday, September 28. The firm earned “Mkt Perform” rating on Monday, October 3 by FBR Capital.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $147.09 million. The company's lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

More important recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: Globenewswire.com which released: “Galectin Therapeutics to Present at BIO CEO & Investor Conference” on February 06, 2018, also Seekingalpha.com published article titled: “NASH Pathogenesis: Better Understanding And A Look At Galectin”, Globenewswire.com published: “Galectin Therapeutics to Present at 30th Annual ROTH Conference” on February 28, 2018. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) was released by: Seekingalpha.com and their article: “Update On Galectin Therapeutics’ Potential Entry Into Cancer Market” with publication date: February 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: